Protara Therapeutics appoints Jathin Bandari as Chief Medical Officer

Protara Therapeutics, Inc.

Dr. Bandari, previously Interim CMO, appointed permanent CMO effective Jan 10, 2022.
Annual base salary of $415,000, discretionary bonus target 40% of base.
Granted stock option for 81,000 shares and RSU for 13,500 shares, subject to board approval.
Severance: 9 months salary plus target bonus and healthcare if terminated without cause or for good reason.
In change of control termination, 100% acceleration of unvested equity.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jathin Bandari

Chief Medical Officer

TARA · Protara Therapeutics, Inc.

Effective: 2022-01-10
Filed: January 10, 2022, 6:59 PM ET

Effective as of January 10, 2022 (the “Effective Date”), Protara Therapeutics, Inc. (the “Company”) appointed Jathin Bandari, M.D. as Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jathin Bandari was appointed as Chief Medical Officer at Protara Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Effective as of January 10, 2022 (the “Effective Date”), Protara Therapeutics, Inc. (the “Company”) appointed Jathin Bandari, M.D. as Chief Medical Officer of the Company.

View on SEC.gov

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-001222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.